Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2025)

Karyopharm Therapeutics' Operating Leases history spans 7 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 14.44% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, down 14.44%, while the annual FY2025 figure was $5.7 million, 14.44% down from the prior year.
  • Operating Leases reached $5.7 million in Q4 2025 per KPTI's latest filing, down from $6.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $10.7 million in Q1 2021 to a low of $955000.0 in Q2 2024.
  • Average Operating Leases over 5 years is $6.2 million, with a median of $6.3 million recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 78.78% in 2024, then soared 554.55% in 2025.
  • A 5-year view of Operating Leases shows it stood at $9.0 million in 2021, then plummeted by 32.02% to $6.1 million in 2022, then tumbled by 54.26% to $2.8 million in 2023, then skyrocketed by 140.66% to $6.7 million in 2024, then fell by 14.44% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Operating Leases are $5.7 million (Q4 2025), $6.0 million (Q3 2025), and $6.3 million (Q2 2025).